Pharsight

Silenor patents expiration

SILENOR Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10653662 CURRAX Methods of using low-dose doxepin for the improvement of sleep
May, 2027

(3 years from now)

US9486437 CURRAX Methods of using low-dose doxepin for the improvement of sleep
May, 2027

(3 years from now)

US9861607 CURRAX Methods of using low-dose doxepin for the improvement of sleep
May, 2027

(3 years from now)

US10238620 CURRAX Methods of using low-dose doxepin for the improvement of sleep
May, 2027

(3 years from now)

US10653660 CURRAX Methods of improving the pharmacokinetics of doxepin
Jul, 2027

(3 years from now)

US11110074 CURRAX Methods of improving the pharmacokinetics of doxepin
Jul, 2027

(3 years from now)

US9572814 CURRAX Methods of improving the pharmacokinetics of doxepin
Jul, 2027

(3 years from now)

US7915307 CURRAX Methods of improving the pharmacokinetics of doxepin
Aug, 2027

(3 years from now)

US11234954 CURRAX Low-dose doxepin for treatment of sleep disorders in elderly patients
Jan, 2028

(4 years from now)

US9907780 CURRAX Low-dose doxepin formulations and methods of making and using the same
Apr, 2028

(4 years from now)

US10548871 CURRAX Low-dose doxepin formulations and methods of making and using the same
Apr, 2028

(4 years from now)

US11096920 CURRAX Low-dose doxepin formulations and methods of making and using the same
Apr, 2028

(4 years from now)

US9107898 CURRAX Methods of using low-dose doxepin for the improvement of sleep
May, 2028

(4 years from now)

US9532971 CURRAX Low-dose doxepin formulations and methods of making and using the same
Jun, 2029

(5 years from now)

US8513299 CURRAX Methods of using low-dose doxepin for the improvement of sleep
Sep, 2030

(6 years from now)

Silenor is owned by Currax.

Silenor contains Doxepin Hydrochloride.

Silenor has a total of 15 drug patents out of which 0 drug patents have expired.

Silenor was authorised for market use on 17 March, 2010.

Silenor is available in tablet;oral dosage forms.

Silenor can be used as treatment of insomnia.

The generics of Silenor are possible to be released after 07 September, 2030.

Drugs and Companies using DOXEPIN HYDROCHLORIDE ingredient

Market Authorisation Date: 17 March, 2010

Treatment: Treatment of insomnia

Dosage: TABLET;ORAL

How can I launch a generic of SILENOR before it's drug patent expiration?
More Information on Dosage

SILENOR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic